Advanced searches left 3/3

Epilepsy Treatment - Europe PMC

Summarized by Plex Scholar
Last Updated: 01 September 2022

* If you want to update the article please login/register

Recommendations for treatment strategies in people with epilepsy during times of shortage of antiseizure medications

People with epilepsy with readily available ASMs can be difficult in times of acute antiseizure medication shortage due to crisis situations. However, for several ASMs, the possibility of an overnight switch to another drug does not exist. Switching from brand to generic or between generic drugs has often been demonstrated to be safe, if necessary. Finally, if benzodiazepines or equipment to administer drugs intravenously are not available, rectal administration of some ASMs may be a vital alternative therapy for treating serial seizures and status epilepticus.

Source link: https://europepmc.org/article/MED/35894673


Development and Validation of a Deep Learning Model for Predicting Treatment Response in Patients With Newly Diagnosed Epilepsy.

Importance Selection of antiseizure drugs for epilepsy is largely a trial-and-error process. With the first ASM for individual patients, the aim was to create and validate a deep learning model using readily available clinical data to predict treatment success. A total of 2404 adults with epilepsy newly treated at specialist clinics in Scotland, Malaysia, Australia, and China between 1982 and 2020, with 606 being refused admission because of missing data in 1 or two variables. This cohort review first pooled all cohorts for model development and testing with the use of the transformer model architecture on 16 academic variables and ASM results. When receiving the first ASM, treatment success was characterized as complete seizure freedom for the first year of therapy. The transformer model's results were compared to other machine learning schemes. The transformer model that was designed with the pooled cohort had an AUROC of 0. 65 and a weighted balanced accuracy of 0. 62 on the test set. The model that was developed using the largest cohort only had AUROCs ranging from 0. 52 to 0. 62 in the external validation cohorts, with varying from 0. 52 to 0. 62. The transformer model that was built using the pooled cohort outperformed 2 of the 5 other models tested in terms of AUROC. Conclusions and importance In this cohort study, a deep learning approach demonstrated the possibility of personalized prediction of response to ASMs based on clinical results.

Source link: https://europepmc.org/article/MED/36036923


Influence of personality profile in patients with drug-resistant epilepsy on quality of life following surgical treatment: A 1-year follow-up study.

At the 1-year follow-up, the aim of this study was to determine the effect of personality profil in patients with drug-resistant epilepsy on quality of life after surgical intervention, as well as comparing the results with a non-surgical control group. The 1-year follow-up, comparing the control and surgical groups, found significant differences in the QoL scores, which were higher in those patients who had undergone surgery. Patients who underwent surgery had improved post-surgical outcomes in the QoL scores, with higher neurological symptoms in the QoL scores, while high neurotic patients had worse QoL results. Patients' QoL changes were correlated with the baseline's personality profile. As compared to the non-surgical group, QoL measures have significantly raised in the surgical group, but no one was linked to baseline or postoperative seizure frequency at 1 year.

Source link: https://europepmc.org/article/MED/35995547


Variability in Serum Concentrations and Clinical Response in Artisanal Versus Pharmaceutical Cannabidiol Treatment of Pediatric Pharmacoresistant Epilepsy.

We hypothesized that serum cannabidiol levels in patients taking pharmaceutical-versus artisanal-CBD oil would be higher in patients receiving pharmaceutical-based cannabidiol solution, and that elevated serum CBD concentrations could lead to elevated side effects and reduced seizure frequency. CBD levels in the mean serum were 51. 1 ng/mL and 124 ng/mL. Patients receiving artisanal-CBD had no change in median overall seizures; the pharmaceutical-CBD group had a median 50% decline. Conclusions In pediatric patients with refractory epilepsy, pharmaceutical-CBD has higher serum CBD levels than artisanal-CBD. These higher CBD levels have been associated with increased reported adverse effects, but there is no difference in seizure frequency.

Source link: https://europepmc.org/article/MED/36042959


Discovery of triazenyl triazoles as Na v 1.1 channel blockers for treatment of epilepsy.

We'll start with triazenylation of rufinamide, and we'll introduce the triazenyl triazoles as a new Na v 1. 1 channel blocker for epilepsy therapy. compound 6a and 6e were discovered to modulate the inactivation voltage of Na v 1. 1 channel with a difference of -10. 07 mv and -11. 28 mV, respectively, as a result of electrophysiological process assay. At an intragastric dose of 50 mg/kg, pentylenetetrazole mouse model, 6a and 6e, reduced the seizure level, prolonged seizure latency, and raised the survival rate of epileptic mice at 6a and 6e.

Source link: https://europepmc.org/article/MED/35985458


Non-pharmacological treatment options of drug-resistant epilepsy in subcortical band heterotopia: systematic review and illustrative case.

Objectives: Subtical band heterotopia is a rare X-linked neuronal migration disorder mainly in females commonly associated with drug-resistant epilepsy. The purpose of this research is to examine the literature on non-pharmacologic treatment alternatives of drug-resistant epilepsy in subcortical band heterotopia. Conclusions The systematic literature review found 25 patients with subcutaneous band heterotopia and drug-resistant epilepsy who underwent non-pharmacological intervention. Ten patients underwent corpus callosotomy, and 8 patients underwent formal temporal lobectomy. Three patients underwent focal cortical resection. According to the Engel Epilepsy Outcome Scale, the results of 2 patients were class I, one patient class II, of 1 patient class III, and 5 patients class IV. Patients with subcortical band heterotopia are unlikely to reach a firm conclusion as to which non-pharmacologic therapy is the most appropriate therapy option for refractive epilepsy in patients with subcortical band heterotopia.

Source link: https://europepmc.org/article/MED/35933521


The effect of phenobarbital treatment on behavioral comorbidities and on the composition and function of the fecal microbiome in dogs with idiopathic epilepsy.

Phenobarbital is one of the most popular antiseizure drugs used to treat canine idiopathic epilepsy. Prior to the start of PB therapy and 90 days after oral PB therapy, Fecal samples of 12 dogs with IE were collected. After 90 days of therapy, Fecal SCFA concentrations and the contents of propionate and butyrate increased significantly in total fecal SCFA concentrations and concentrations, as well as butyrate, butyrate concentrations revealed upward trend. After 90 days of PB's treatment, improvement was seen in stranger-directed anxiety, non-social anxiety, and trainingability, according to cBARQ's report, although there were no differences in ADHD-like behaviour and canine cognitive dysfunction ratings after 90 days of PB treatment. Although only modest changes in bacterial taxonomy were found, the higher SCFA concentrations after PB treatment could be one of the key differences between PB-R and PB-NR.

Source link: https://europepmc.org/article/MED/35990279


Centromedian thalamic neuromodulation for the treatment of idiopathic generalized epilepsy.

Despite an increase in the number of available anti-seizure drugs, 20% to 30% of people with IGE experience seizures, despite safe medication trials. Unlike focal epilepsy, resective surgery is not a viable treatment option for IGE; however, neuromodulation may be a safe surgical treatment for people with IGE.

Source link: https://europepmc.org/article/MED/35992953


Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain.

In the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain, it was determined by the economically viable price of cenobamate to become a cost-effective alternative compared to third-generation anti-seizure drugs. Cenobamate dominates all treatment alternatives for the national health system, with a daily price of u20ac5. 45. Conclusions Cenobamate-based therapy of FOS in adult patients with DRE in Spain could result in incremental health improvement over third-generation ASMs, and in the base case, EJP may be a cost-effective solution for the adjunctive treatment of FOS in adult patients with DRE.

Source link: https://europepmc.org/article/MED/35904256


Distal renal tubular acidosis and lethargy associated with zonisamide treatment in a dog with idiopathic epilepsy.

This is the first study to show that after compensation for the plasma bicarbonate concentration by a sodium bicarbonate infusion was approximately 5%, suggesting distal renal tubular acidosis. The serum zonisamide concentration decreased, but adverse effects were not reduced by lowering the zonisamide dose.

Source link: https://europepmc.org/article/MED/35916390

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions